Table 4 Factors associated with local progression in HCCs showing a complete response according to mRECIST and complete lipiodol retention
With local progression N = 10 | Without Local progression N = 20 | p value* | |
|---|---|---|---|
Serum AFP level (μg /L) ± SD | 31 ± 36 | 124 ± 340 | 0.40 |
HCC size (mm) ± SD | 22 ± 9 | 23 ± 12 | 0.78 |
HCC location | |||
- Right lobe | 9 (90%) | 14 (70%) | 0.22 |
- Left Lobe | 1 (10%) | 6 (30%) | |
Capsule Appearance | 3 (30%) | 7 (35%) | 0.14 |
CBCT guidance | 3 (30%) | 10 (50%) | 0.44 |
Selective cTACE Treatment | 8 (80%) | 15 (75%) | 0.76 |
Mean Delivered Dose (mg) ± SD | 19 ± 12 | 29 ± 14 | <0.01 |
Presence of gas on follow-up CT | 1 (10%) | 0 (0%) | 0.33 |
Embolization Agent | |||
- Gelitaspon | 10 (100%) | 16 (80%) | 0.48 |
- PVA particles | 0 (0%) | 3 (15%) | |
- No embolization | 0 (0%) | 1 (5%) | |